physostigmine salicylate, an acetylcholinesterase inhibitor. ▪ INDICATIONS: It is an ophthalmic preparation prescribed as a miotic agent for the treatment of glaucoma, and it is administered systemically for treating the toxic effects of excessive cholinergic receptors blockade (e.g., resulting from atropine poisoning). ▪ CONTRAINDICATIONS: Asthma, gangrene, diabetes, cardiovascular disease, or mechanical obstruction of the intestines or urinary tract prohibits its use. It is also not administered to patients in any vagotonic state or to those receiving choline esters or depolarizing neuromuscular blocking agents. ▪ ADVERSE EFFECTS: Among the adverse effects are hypersalivation, diaphoresis, lacrimation, miosis, bradycardia, palpitations, nervousness, and convulsions.
